Standout Papers

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Even... 2014 2026 2018 2022 307
  1. Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531 (2014)
    Alan S. Gamis, Todd A. Alonzo et al. Journal of Clinical Oncology

Immediate Impact

56 standout
Sub-graph 1 of 23

Citing Papers

Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release
2024 Standout
The interaction of innate immune and adaptive immune system
2024 Standout
7 intermediate papers

Works of Patti Byron being referenced

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
2014 Standout
Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531
2013

Author Peers

Author Last Decade Papers Cites
Patti Byron 259 111 143 126 8 353
Kathleen Glick 273 115 153 129 9 371
JN Winter 283 151 95 76 11 401
AC Homans 140 119 139 72 12 317
G. J. Dovey 127 163 148 72 10 366
A Nandi 318 155 56 167 11 391
M. M. A. Rottier 99 175 177 149 9 386
Henrik Schr�der 149 93 232 58 13 369
G. Zeile 366 104 106 84 6 409
AT Look 178 122 212 98 8 350
G Prentice 207 70 61 103 12 378

All Works

Loading papers...

Rankless by CCL
2026